Karyopharm Therapeutics Inc (KPTI)

1.06 0.00 (0.00%) USD  |  NASDAQ  |  Apr 26, 16:00
1.05 -0.01 (-0.94%) After-Hours: 20:00
More

Karyopharm Therapeutics Research and Development Expense (Quarterly): 39.38M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2012. Upgrade now.
Date Value
December 31, 2023 39.38M
September 30, 2023 35.55M
June 30, 2023 31.48M
March 31, 2023 32.34M
December 31, 2022 30.93M
September 30, 2022 31.36M
June 30, 2022 44.31M
March 31, 2022 42.06M
December 31, 2021 44.00M
September 30, 2021 45.81M
June 30, 2021 33.98M
March 31, 2021 37.05M
December 31, 2020 37.18M
September 30, 2020 37.04M
June 30, 2020 42.59M
March 31, 2020 34.00M
December 31, 2019 31.58M
September 30, 2019 26.27M
June 30, 2019 26.52M
March 31, 2019 37.97M
December 31, 2018 38.89M
September 30, 2018 36.43M
June 30, 2018 44.73M
Date Value
March 31, 2018 41.32M
December 31, 2017 34.83M
September 30, 2017 25.24M
June 30, 2017 23.12M
March 31, 2017 24.08M
December 31, 2016 20.67M
September 30, 2016 19.89M
June 30, 2016 24.58M
March 31, 2016 21.80M
December 31, 2015 24.06M
September 30, 2015 25.92M
June 30, 2015 27.01M
March 31, 2015 20.75M
December 31, 2014 20.04M
September 30, 2014 15.95M
June 30, 2014 13.16M
March 31, 2014 10.98M
December 31, 2013 9.689M
September 30, 2013 7.738M
June 30, 2013 6.06M
March 31, 2013 4.965M
December 31, 2012 3.666M
September 30, 2012 2.997M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

26.27M
Minimum
Sep 2019
45.81M
Maximum
Sep 2021
35.97M
Average
35.55M
Median
Sep 2023

Research and Development Expense (Quarterly) Benchmarks

Geron Corp 32.91M
Arbutus Biopharma Corp 17.56M
Verastem Inc 22.50M
Actinium Pharmaceuticals Inc 8.118M
Chimerix Inc 15.64M